FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVID APPR	ROVAL
OMB Number:	3235-028
Estimated average I	burden
hours per response	0.1

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person *- VERU DENNISON T					2. Issuer Name and Ticker or Trading Symbol Brickell Biotech, Inc. [BBI]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102				3. Date of Earliest Transaction (Month/Day/Year) 06/14/2021							Officer (give t	tle below)	Other	(specify below)	
(Street) BOULDER, CO 80301			4. If A								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Ci		(State)	(Zip)				Tal	ble I - Non-	Deriv	vative Securi	ties Acqui	red, Disposed o	f, or Benefi	cially Owned		
1.Title of S (Instr. 3)	title of Security tr. 3) 2. Transaction Date (Month/Day/Yea		ear) Exe	2A. Deemed Execution Da any (Month/Day/		Coo (In:	Fransaction de str. 8)	(A (Ir	Securities Ac A) or Disposed nstr. 3, 4 and 5 (A) or mount (D)	1 of (D) (5)	5. Amount of Sec Dwned Followin Fransaction(s) Instr. 3 and 4)	s) .		Ownership Form: Direct (D) or Indirect I) Instr. 4)	Beneficial Ownership	
1 77:1		la m		(e.g.		s, calls, w	arra	nts, options	s, con	sed of, or Ben	rities)		lon:	lo xi	c 110	11.37
1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	(e.g.	, put	5. Numb	arra er ative	curr Acquired, D	oispos s, con tercisa Date	y valid OMB sed of, or Ben evertible secu able and	rities)	ond Amount of ng Securities	8. Price of	9. Number o Derivative Securities	f 10.	11. Natur of Indirec Beneficia
(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)							(Instr. 5)	Beneficially Owned Following Reported Transaction(s	Security Direct (I or Indire	D) ect
				Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(IIISII. 4 ₂	
Stock Option (right to buy)	\$ 0.90	06/14/2021		A		40,000		06/14/20)22	06/14/2031	Commo	140.000.00	\$ 0	40,000	D	
Repor	ting O	wners														

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
VERU DENNISON T C/O BRICKELL BIOTECH, INC. 5777 CENTRAL AVENUE, SUITE 102 BOULDER, CO 80301	X					

Signatures

/s/ Christine G. Long, Attorney-in-Fact for Dennison T. Veru (power of attorney previously filed)	06/14/2021
Signature of Reporting Person	Date

Explanation of Responses:

- $_{\star}$ $\,$ If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.